News

With 51% Year-over-Year Growth, Alafair Biosciences moves up 41 spots to No. 13 on the Inc. Regionals: Southwest List

Inc. Names Alafair Biosciences' Sarah Mayes, Ph.D. to Its 2025 Female Founders 500 List

Alafair Biosciences Reports Strong Growth in 2024

Alafair Biosciences Celebrates Over 22,000 Implants of VersaWrap® Hydrogel Sheet in Patients

For the Second Year, Alafair Biosciences Makes Inc. 5000, With Three-Year Revenue Growth of 597%

Alafair Biosciences Awarded Synthetic Implantable Products Agreement with Premier, Inc. for VersaWrap® Hydrogel Sheet

Alafair Biosciences Receives Innovative Technology Contract from Vizient for VersaWrap®

Alafair Biosciences reports record-breaking 2023 business results

Alafair Biosciences Ranks No. 54 on 2024 Inc. 5000 Regional Southwest's Fastest-Growing Private Companies, Posting 2-Year Revenue Growth of 234%

Alafair Biosciences Announces 12,000+ VersaWrap® Implants in Patients

Alafair Biosciences Selected to Exhibit VersaWrap at Vizient Innovative Technology Exchange

Alafair recognized as Austin’s Fast Growing Medical Device Company

Alafair Biosciences is Named a Best Place to Work by Austin Business Journal

Alafair Biosciences Announces VersaWrap® Sales Milestone

Alafair Enrolls Tenth Patient in Distal Radius Fracture Clinical Study

Alafair Enrolls First Patient in Hand Tendon Clinical Study

Eric Giza, MD, FACS Joins Alafair Biosciences Scientific & Clinical Advisory Board

Alafair Biosciences launches VersaWrap, a plant-based, non-collagen, bioresorbable interface for tendon and/or peripheral nerve

Alafair Biosciences appoints John Joyoprayitno as new President and CEO

Alafair Biosciences Receives 510(k) Clearance for VersaWrap® Nerve Protector

Alafair Biosciences Announces VersaWrap® Tendon Protector Sales Milestone

Alafair Biosciences Raises Over $7.2 Million in Series B/B-1 Financing

Alafair Biosciences Launches VersaWrap Tendon Protector

Alafair Biosciences Receives FDA 510(k) Clearance for VersaWrap Tendon Protector